The pharmaceuticals laboratory supports North Asia with formulation development, reverse engineering, troubleshooting, and analysis for various dosage forms
Addresses brain metastases harboring BRCA1/2 and/or HRR alterations—an area of high unmet need
These medicines are essential in preventing RhD immunisation during pregnancy
Approval based on NIAGARA Phase III trial results which showed a 32% reduction in the risk of recurrence and a 25% reduction in the risk of death for the Imfinzi regimen vs. neoadjuvant chemotherapy alone
ARGX-119 is the sixth molecule developed through our Immunology Innovation Program to show proof-of-concept
The company has confirmed that the deceased are 39
The acquisition of Pivya is an important step in Alembic’s ability to provide branded pharmaceutical product to the US Healthcare market
The site, spanning approximately 25,000 square meters, is expected to commence operations by the end of 2025
Enhance strategies to drive sustainability, global Reach and digital transformation for a trillion-dollar future
A triple-action Formula for comprehensive respiratory relief
Subscribe To Our Newsletter & Stay Updated
